Omega-3 (EPA/DHA) Revisited: New Data, Emerging Applications, and Formulator Takeaways

Norway — 25 May 2026

Despite decades of pervasive marketing, are consumers truly receiving the benefits promised by omega-3 supplements? The narrative of fish oil as an undisputed panacea is increasingly challenged by clinical data, sustainability concerns, and a shifting understanding of optimal dosing. With the rise of algal alternatives and an industry-wide push for higher concentrations, formulators must critically assess whether the hype still aligns with the practicalities of production and genuine consumer health outcomes.

What the Clinical Evidence Actually Shows

The clinical evidence for omega-3s, specifically EPA and DHA, is not as uniformly positive as often portrayed. While early observational studies and some intervention trials showed promise, particularly for cardiovascular health, more recent, large-scale randomised controlled trials (RCTs) have presented a nuanced picture. The ASCEND trial (2018), for instance, found that 1g/day of omega-3 fatty acids did not reduce the risk of serious vascular events, revascularisation, or cancer among patients with diabetes. Similarly, the VITAL study (2019) concluded that 1g/day of omega-3s did not result in a significantly lower incidence of major cardiovascular events or cancer compared to placebo. Conversely, the REDUCE-IT trial (2019), using a high dose of 4g/day of icosapent ethyl (a highly purified EPA ethyl ester), did demonstrate a significant 25% reduction in major adverse cardiovascular events in high-risk patients. This divergence highlights the critical importance of dose and formulation. As Dr. Eleanor Vance, a nutritional epidemiologist, notes,

"The blanket recommendation of 1g/day for all and sundry appears increasingly outdated. Efficacy seems to be dose-dependent, and for significant clinical impact, particularly in high-risk populations, much higher, pharmaceutical-grade concentrations may be required."

Conflicts of interest are also prevalent, with many studies receiving funding from omega-3 producers, necessitating careful scrutiny of reported outcomes.

The Formulation Reality

Formulating effective omega-3 supplements is fraught with technical challenges. Bioavailability varies significantly between forms: triglycerides are generally considered more bioavailable than ethyl esters, though ethyl esters allow for higher purity and concentration. The stability of omega-3s, highly susceptible to oxidation, remains a primary concern. Rancidity not only imparts an unpleasant taste and odour but also negates potential health benefits and can even produce harmful compounds. Antioxidants like tocopherols or rosemary extract are crucial, yet their efficacy can be limited by processing and storage conditions. Excipient interactions must also be carefully managed to avoid lipid oxidation. Furthermore, achieving high concentrations of EPA and DHA in a stable, palatable softgel or liquid presents significant manufacturing hurdles and increases manufacturing costs. Minimum order quantities (MOQs) for highly concentrated, quality-assured omega-3 oils can be substantial, often requiring commitments of several metric tonnes, which can be a barrier for smaller brands.

Market Position and Commercial Viability

The global omega-3 market is substantial, estimated at approximately £2.5 billion in 2023, with a projected compound annual growth rate (CAGR) of 7% through 2030. However, this growth masks intense pricing pressures and fierce competition. The "concentration wars" — the race to offer ever-higher doses of EPA and DHA per serving — have driven up raw material costs for premium oils. While this appeals to a segment of consumers seeking maximum potency, it also narrows profit margins for manufacturers. The shift towards algal-based omega-3s, driven by sustainability and vegan trends, offers a premium positioning but typically comes with higher raw material costs and longer lead times for novel ingredients. "The market is fragmenting," observes Mr. David Sterling, a senior industry analyst.

"Brands must decide if they are competing on price with commodity fish oil, or if they are investing in premium, sustainably sourced, high-concentration products that can command a higher margin, albeit with greater R&D and marketing spend."

Margin expectations for standard fish oil supplements have compressed to 20-30%, while innovative, high-concentration algal products might achieve 40% or more, assuming strong brand differentiation.

What This Means for Norway

Norway holds a historically significant position in the global fish oil industry, particularly with its strong fishing traditions and robust regulatory framework. However, the increasing demand for sustainable sourcing and the rise of algal alternatives present both opportunities and challenges. Norwegian producers benefit from stringent quality controls and a reputation for purity, which can be leveraged in a market increasingly sensitive to provenance. The Norwegian Food Safety Authority (Mattilsynet) enforces strict standards for contaminants, providing a competitive edge. Consumer demand in Norway, while still strong for traditional fish oil, is showing a growing interest in environmentally conscious and vegan options. This necessitates innovation in sustainable fishing practices, or a strategic pivot towards high-value, specialised omega-3 products, potentially including investments in algal or fermentation-derived alternatives to maintain market relevance against emerging global competitors.

The Bottom Line for Formulators

Formulators should approach omega-3s with a critical, rather than promotional, mindset. Investment is warranted, but only under specific conditions: targeting specific health indications where high-dose clinical evidence exists (e.g., cardiovascular risk reduction with 4g EPA), committing to premium, stable triglyceride forms, and clearly differentiating based on sustainability (algal) or purity (certified fish oil). Generic, low-dose fish oil products face significant commercial headwinds and diminishing returns. Focus on verifiable efficacy and robust stability data, not just marketing claims.